A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes
Study Details
Study Description
Brief Summary
The purpose of this study is to study the effect of LY2189265 on how the body absorbs and processes a Type 2 Diabetes Mellitus (T2DM) drug (sitagliptin) and how sitagliptin affects LY2189265 when they are taken together.
The duration of participation in this study is expected to be approximately 61 days. The study requires 2 clinic confinements (one of 2 nights and one of 19 nights duration).
The study involves 3 injections, subcutaneous, of 1.5 milligrams (mg) LY2189265 and 18 daily doses of 100 mg sitagliptin tablets administered orally.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: LY2189265, Sitagliptin + LY2189265 A single 1.5-milligram (mg) dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). |
Biological: LY2189265
Administered subcutaneously
Other Names:
Drug: Sitagliptin
Administered orally
|
| Experimental: Sitagliptin + LY2189265, LY2189265 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). There was a washout of at least 21 days before crossing over and receiving a single 1.5 mg dose of LY2189265 administered subcutaneously (Treatment 1). |
Biological: LY2189265
Administered subcutaneously
Other Names:
Drug: Sitagliptin
Administered orally
|
Outcome Measures
Primary Outcome Measures
- Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Sitagliptin [Predose and up to 24 hours postdose on Day 4, Day 6, and Day 13 of Treatment 2]
Area under the sitagliptin pharmacokinetic (PK) concentration versus time curve (AUC [0-tau]) during one dosing interval (24 hours) is summarized.
- Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Sitagliptin [Predose and up to 24 hours postdose on Day 4, Day 6, and Day 13 of Treatment 2]
Secondary Outcome Measures
- Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Sitagliptin [Predose and up to 24 hours post dose on Day 4, Day 6, and Day 13 of Treatment 2]
- Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY2189265 [Predose and up to 168 hours postdose on Day 1 of Treatment 1 and on Day 5 and Day 12 of Treatment 2]
Area under the LY2189265 pharmacokinetic (PK) concentration versus time curve (AUC [0-tau]) during one dosing interval (168 hours) is summarized.
- Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of LY2189265 [Predose and up to 168 hours postdose on Day 1 of Treatment 1 and on Day 5 and Day 12 of Treatment 2]
- Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of LY2189265 [Predose and up to 168 hours postdose on Day 1 of Treatment 1 and on Day 5 and Day 12 of Treatment 2]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
are males or females, diagnosed with T2DM (Type 2 Diabetes Mellitus) for ≥3 months prior to screening
-
male participants with female partners of child-bearing potential, or partners who are pregnant or breastfeeding, agree to use a reliable method of contraception from the time of the first dose until 3 months after the last dose of investigational product, as determined by the investigator. The method may be one of the following:
-
condom with spermicidal agent
-
male participant sterilization
-
true abstinence (which is in line with the participant's usual lifestyle choice; withdrawal or calendar methods are not considered acceptable)
-
female participants not of child-bearing potential (that is, are postmenopausal or permanently sterilized [such as, tubal occlusion, hysterectomy, bilateral salpingectomy]). Such participants will not be required to use contraception but must test negative for pregnancy at the time of enrollment. Postmenopausal is defined as at least 1 year post cessation of menses (without an alternative medical cause) or at least 1 year of spontaneous amenorrhea, with follicle stimulating hormone (FSH) ≥40 milli-international units/milliliter (mIU/mL)
-
female participants who have undergone sterilization by tubal ligation: agree to use a condom in conjunction with spermicidal gel, foam, cream, film or suppository from the time of screening until 3 months after the last dose of investigational product. Such participants must also test negative for pregnancy at the time of enrollment
-
have a body mass index (BMI) of between 23.0 and 40.0 kilograms/meter squared (kg/m^2), inclusive, at the time of screening
-
have T2DM controlled with diet and exercise alone, or are on a stable dose of metformin Immediate Release (IR) for at least 4 weeks prior to screening, or are on metformin Extended Release (ER) and are capable/willing to be switched onto metformin IR or washed out prior to the first dose of investigational product, or are on sulfonylureas, acarbose (or other disaccharidase inhibitors), thiazolidinediones, or meglitinides and are capable/willing to be washed out prior to the first dose of investigational product
-
have a fasting blood glucose value at screening ≤15.3 millimoles/liter (mmol/L) (275 milligrams/deciliter [mg/dL])
-
have a glycosylated hemoglobin A1c (HbA1c) value at screening (or within 4 weeks prior to screening) of 6.5% to 10%
-
have clinical laboratory test results within normal reference range for the population or within normal reference range for the investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator. Abnormalities of serum glucose, serum lipids, urinary glucose, and urinary protein consistent with T2DM are acceptable.
-
have creatinine clearance (CrCl) of greater than 50 milliliters/minute (mL/min) at screening estimated by the Cockcroft-Gault formula
-
have venous access sufficient to allow for blood sampling as per the protocol
-
are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
Exclusion Criteria:
-
are currently enrolled in, have completed or discontinued within the last 30 days from, a clinical trial involving an investigational product, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
-
have known allergies to glucagon-like-peptide 1 (GLP-1)-related compounds, including LY2189265 or to sitagliptin-related compounds or any components of either formulation
-
are persons who have previously completed or withdrawn from this study or any other study investigating LY2189265 in the 3 months prior to screening or have received glucagon-like peptides or incretin mimetics in the 3 months prior to screening
-
have taken insulin, chlorpropamide, or alpha-glucosidase inhibitors within 30 days prior to screening
-
have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
-
have poorly controlled hypertension (systolic blood pressure [BP] >160 millimeters of mercury [mmHg] and/or diastolic BP >100 mmHg) and/or evidence of labile BP including symptomatic postural hypotension
-
have a history or presence of respiratory, hepatic, renal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
-
have a history or presence of cardiovascular disorder (including myocardial infarction, cerebrovascular accident, venous thromboembolism, arrhythmia [judged by the investigator to be clinically significant], or angina) within the last year, have symptoms or signs of congestive heart failure, or are expected to require coronary artery bypass surgery or angioplasty
-
have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) or gastrointestinal disorder, for example relevant esophageal reflux or gall bladder disease, or any gastrointestinal disease which impacts gastric emptying (GE) (such as, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by GLP-1 analogs or dipeptidyl peptidase-4 (DPP-4) inhibitors. Participants with dyslipidemia, and participants who had cholecystolithiasis (removal of gall stones) and/or cholecystectomy (removal of gall bladder) in the past, with no further sequelae, may be included in the study at the discretion of the screening physician
-
have any existing medical condition that might interfere with interpretation of the data, including a history of gastrointestinal surgery (with the exception of appendectomy performed more than 12 months ago), peptic ulceration, gastrointestinal bleeding, diabetic gastroparesis, ulcerative colitis, Crohn's disease, Irritable Bowel Syndrome (IBS), gastric bypass, or laparoscopic gastric banding
-
show evidence of significant active neuropsychiatric disease
-
have had 2 or more episodes of severe hypoglycemia within the last 6 months prior to screening
-
have personal or family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC
-
regularly uses known drugs of abuse and/or show positive findings on urinary drug screening
-
intend to start new concomitant medication during the study, including over-the-counter and herbal medication, regularly use drugs that directly reduce gastrointestinal motility and/or regularly use systemic corticosteroids by oral, intravenous, or intramuscular route, or potent, inhaled, or intranasal steroids known to have a high rate of systemic absorption
-
show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
-
show evidence of hepatitis C and/or positive hepatitis C antibody
-
show evidence of hepatitis B and/or positive hepatitis B surface antigen
-
have donated blood of more than 500 milliliters (mL) within the last month prior to screening
-
have an average weekly alcohol intake that exceeds 21 units per week (males up to age
- and 14 units per week (males over 65 and females), or are unwilling to stop alcohol consumption from Day -3 of each period until after the last pharmacokinetic (PK) sample has been taken for that period, or to limit alcohol intake to a maximum of 2 units/day on all other days from screening through to follow-up. (1 unit = 12 ounces [oz] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
-
smoke more than 10 cigarettes (or equivalent in nicotine) per day, and are unwilling to refrain from smoking on the day of LY2189265/sitagliptin administration or are unable to abide by Clinical Research Unit (CRU) restrictions on other inpatient days
-
are participants who, in the opinion of the investigator, are in any way unsuitable to participate in the study
-
have any medical conditions, medical history or are taking any medication which are contraindicated
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Daytona Beach | Florida | United States | 32117 |
| 2 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Honolulu | Hawaii | United States | 96814 |
| 3 | For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. | Dallas | Texas | United States | 75247 |
Sponsors and Collaborators
- Eli Lilly and Company
Investigators
- Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 14361
- H9X-MC-GBDW
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | LY2189265, Sitagliptin + LY2189265 | Sitagliptin + LY2189265, LY2189265 |
|---|---|---|
| Arm/Group Description | First Intervention Period: A single 1.5-milligram (mg) subcutaneous (SC) injection of LY2189265 on Day 1 (Treatment 1). Second Intervention Period: 100 mg of sitagliptin, administered orally, once daily on Day 1 to Day 18 with single SC injections of 1.5 mg LY2189265 immediately prior to the sitagliptin dose on Day 5 and Day 12 (Treatment 2). There was a washout of at least 21 days between treatments. | First Intervention Period: 100 mg of sitagliptin, administered orally, once daily on Day 1 to Day 18 with single SC injections of 1.5 mg LY2189265 immediately prior to the sitagliptin dose on Day 5 and Day 12 (Treatment 2). Second Intervention Period: A single 1.5-mg SC injection of LY2189265 on Day 1 (Treatment 1). There was a washout of at least 21 days between treatments. |
| Period Title: First Intervention | ||
| STARTED | 18 | 11 |
| Received at Least 1 Dose of Drug | 18 | 11 |
| COMPLETED | 18 | 8 |
| NOT COMPLETED | 0 | 3 |
| Period Title: First Intervention | ||
| STARTED | 18 | 8 |
| COMPLETED | 18 | 8 |
| NOT COMPLETED | 0 | 0 |
| Period Title: First Intervention | ||
| STARTED | 18 | 8 |
| COMPLETED | 16 | 8 |
| NOT COMPLETED | 2 | 0 |
Baseline Characteristics
| Arm/Group Title | Entire Study Population |
|---|---|
| Arm/Group Description | Participants who received at least one dose of study drug (LY2189265 or Sitagliptin). |
| Overall Participants | 29 |
| Age (years) [Mean (Standard Deviation) ] | |
| Mean (Standard Deviation) [years] |
52.7
(11.1)
|
| Sex: Female, Male (Count of Participants) | |
| Female |
10
34.5%
|
| Male |
19
65.5%
|
| Ethnicity (NIH/OMB) (Count of Participants) | |
| Hispanic or Latino |
5
17.2%
|
| Not Hispanic or Latino |
24
82.8%
|
| Unknown or Not Reported |
0
0%
|
| Race (NIH/OMB) (Count of Participants) | |
| American Indian or Alaska Native |
0
0%
|
| Asian |
4
13.8%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
| Black or African American |
14
48.3%
|
| White |
11
37.9%
|
| More than one race |
0
0%
|
| Unknown or Not Reported |
0
0%
|
| Region of Enrollment (participants) [Number] | |
| United States |
29
100%
|
Outcome Measures
| Title | Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Sitagliptin |
|---|---|
| Description | Area under the sitagliptin pharmacokinetic (PK) concentration versus time curve (AUC [0-tau]) during one dosing interval (24 hours) is summarized. |
| Time Frame | Predose and up to 24 hours postdose on Day 4, Day 6, and Day 13 of Treatment 2 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Participants who received at least one dose of sitagliptin with evaluable sitagliptin AUC data. |
| Arm/Group Title | 100 mg Sitagliptin (Day 4) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 6) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 13) |
|---|---|---|---|
| Arm/Group Description | Sitagliptin + LY2189265: 100 milligrams (mg) of sitagliptin, administered orally, once daily on Day 1 to Day 18 with single subcutaneous (SC) injections of 1.5 mg LY2189265 immediately prior to the sitagliptin dose on Day 5 and Day 12 (Treatment 2). Measure taken at Day 4. | Sitagliptin + LY2189265: 100 mg of sitagliptin, administered orally, once daily on Day 1 to Day 18 with single SC injections of 1.5 mg LY2189265 immediately prior to the sitagliptin dose on Day 5 and Day 12 (Treatment 2). Measure taken at Day 6. | Sitagliptin + LY2189265: 100 mg of sitagliptin, administered orally, once daily on Day 1 to Day 18 with single SC injections of 1.5 mg LY2189265 immediately prior to the sitagliptin dose on Day 5 and Day 12 (Treatment 2). Measure taken at Day 13. |
| Measure Participants | 28 | 29 | 26 |
| Geometric Mean (Geometric Coefficient of Variation) [nanograms times hour/milliliter(ng*h/mL)] |
3210
(34)
|
3240
(36)
|
2970
(54)
|
| Title | Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Sitagliptin |
|---|---|
| Description | |
| Time Frame | Predose and up to 24 hours postdose on Day 4, Day 6, and Day 13 of Treatment 2 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Participants who received at least one dose of sitagliptin with evaluable sitagliptin Cmax data. |
| Arm/Group Title | 100 mg Sitagliptin (Day 4) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 6) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 13) |
|---|---|---|---|
| Arm/Group Description | Sitagliptin + LY2189265: 100 milligrams (mg) of sitagliptin, administered orally, once daily on Day 1 to Day 18 with single subcutaneous (SC) injections of 1.5 mg LY2189265 immediately prior to the sitagliptin dose on Day 5 and Day 12 (Treatment 2). Measure taken at Day 4. | Sitagliptin + LY2189265: 100 mg of sitagliptin, administered orally, once daily on Day 1 to Day 18 with single SC injections of 1.5 mg of LY2189265 immediately prior to the sitagliptin dose on Day 5 and Day 12 (Treatment 2). Measure taken at Day 6. | Sitagliptin + LY2189265: 100 mg of sitagliptin, administered orally, once daily on Day 1 to Day 18 with single SC injections of 1.5 mg LY2189265 immediately prior to the sitagliptin dose on Day 5 and Day 12 (Treatment 2). Measure taken at Day 13. |
| Measure Participants | 28 | 29 | 27 |
| Geometric Mean (Geometric Coefficient of Variation) [nanograms/milliliter (ng/mL)] |
417
(46)
|
374
(61)
|
318
(77)
|
| Title | Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Sitagliptin |
|---|---|
| Description | |
| Time Frame | Predose and up to 24 hours post dose on Day 4, Day 6, and Day 13 of Treatment 2 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Participants who received at least one dose of sitagliptin with evaluable sitagliptin tmax data |
| Arm/Group Title | 100 mg Sitagliptin (Day 4) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 6) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 13) |
|---|---|---|---|
| Arm/Group Description | Sitagliptin + LY2189265: 100 milligrams (mg) of sitagliptin, administered orally, once daily on Day 1 to Day 18 with single subcutaneous (SC) injections of 1.5 mg LY2189265 immediately prior to the sitagliptin dose on Day 5 and Day 12 (Treatment 2). Measure taken at Day 4. | Sitagliptin + LY2189265: 100 mg of sitagliptin, administered orally, once daily on Day 1 to Day 18 with single SC injections of 1.5 mg LY2189265 immediately prior to the sitagliptin dose on Day 5 and Day 12 (Treatment 2). Measure taken at Day 6. | Sitagliptin + LY2189265: 100 mg of sitagliptin, administered orally, once daily on Day 1 to Day 18 with single SC injections of 1.5 mg LY2189265 immediately prior to the sitagliptin dose on Day 5 and Day 12 (Treatment 2). Measure taken at Day 13. |
| Measure Participants | 28 | 29 | 27 |
| Median (Full Range) [hours] |
1.00
|
2.00
|
2.00
|
| Title | Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY2189265 |
|---|---|
| Description | Area under the LY2189265 pharmacokinetic (PK) concentration versus time curve (AUC [0-tau]) during one dosing interval (168 hours) is summarized. |
| Time Frame | Predose and up to 168 hours postdose on Day 1 of Treatment 1 and on Day 5 and Day 12 of Treatment 2 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Participants who received at least one dose of LY2189265 with evaluable LY2189265 AUC data. |
| Arm/Group Title | 1.5 mg LY2189265 (Day 1) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 5) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 12) |
|---|---|---|---|
| Arm/Group Description | Sitagliptin + LY2189265: A single, 1.5-milligram (mg) dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). Measure taken on Day 1 of Treatment 1. | Sitagliptin + LY2189265: A single, 1.5-mg dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). Measure taken on Day 5 of Treatment 2. | Sitagliptin + LY2189265: A single, 1.5-mg dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). Measure taken on Day 12 of Treatment 2. |
| Measure Participants | 26 | 27 | 26 |
| Geometric Mean (Geometric Coefficient of Variation) [nanograms times hour/milliliter(ng*h/mL)] |
6590
(40)
|
8890
(26)
|
13900
(26)
|
| Title | Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of LY2189265 |
|---|---|
| Description | |
| Time Frame | Predose and up to 168 hours postdose on Day 1 of Treatment 1 and on Day 5 and Day 12 of Treatment 2 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Participants who received at least one dose of LY2189265 with evaluable LY2189265 Cmax data. |
| Arm/Group Title | 1.5 mg LY2189265 (Day 1) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 5) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 12) |
|---|---|---|---|
| Arm/Group Description | Sitagliptin + LY2189265: A single, 1.5-mg dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5 mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). Measure taken on Day 1 of Treatment 1. | Sitagliptin + LY2189265: A single, 1.5-mg dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5 mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). Measure taken on Day 5 of Treatment 2. | Sitagliptin + LY2189265: A single, 1.5-mg dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5 mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). Measure taken on Day 12 of Treatment 2. |
| Measure Participants | 26 | 29 | 26 |
| Geometric Mean (Geometric Coefficient of Variation) [nanograms/milliliter (ng/mL)] |
52.9
(37)
|
68.1
(25)
|
101
(28)
|
| Title | Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of LY2189265 |
|---|---|
| Description | |
| Time Frame | Predose and up to 168 hours postdose on Day 1 of Treatment 1 and on Day 5 and Day 12 of Treatment 2 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Participants who received at least one dose of LY2189265 with evaluable LY2189265 tmax data. |
| Arm/Group Title | 1.5 mg LY2189265 (Day 1) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 5) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 12) |
|---|---|---|---|
| Arm/Group Description | Sitagliptin + LY2189265: A single, 1.5-mg dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). Measure taken on Day 1 of Treatment 1. | Sitagliptin + LY2189265: A single, 1.5-mg dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). Measure taken on Day 5 of Treatment 2. | Sitagliptin + LY2189265: A single, 1.5-mg dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). Measure taken on Day 12 of Treatment 2. |
| Measure Participants | 26 | 29 | 26 |
| Median (Full Range) [hours] |
72.0
|
72.0
|
59.8
|
Adverse Events
| Time Frame | ||||||
|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | ||||||
| Arm/Group Title | LY2189265 | Sitagliptin | Sitagliptin + LY2189265 | |||
| Arm/Group Description | LY2189265: a single, 1.5-milligram (mg) dose of LY2189265 administered subcutaneously on Day 1 of Treatment 1 Time frame: Treatment 1 | Sitagliptin: 100-mg dose of sitagliptin, administered orally, once daily before the LY2189265 dose on Day 1 to Day 5 of Treatment 2. Time Frame: Day 1 to Day 5 of Treatment 2 | Sitagliptin + LY2189265: 100-mg dose of sitagliptin administered orally, once daily from Day 5 to Day 18 of Treatment 2 in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 of Treatment 2. Time Frame: Day 5 to end of Treatment 2 | |||
All Cause Mortality |
||||||
| LY2189265 | Sitagliptin | Sitagliptin + LY2189265 | ||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | / (NaN) | |||
Serious Adverse Events |
||||||
| LY2189265 | Sitagliptin | Sitagliptin + LY2189265 | ||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/26 (0%) | 0/29 (0%) | 2/29 (6.9%) | |||
| Infections and infestations | ||||||
| Pneumonia bacterial | 0/26 (0%) | 0 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
| Injury, poisoning and procedural complications | ||||||
| Concussion | 0/26 (0%) | 0 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
| Renal and urinary disorders | ||||||
| Renal failure acute | 0/26 (0%) | 0 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
Other (Not Including Serious) Adverse Events |
||||||
| LY2189265 | Sitagliptin | Sitagliptin + LY2189265 | ||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 11/26 (42.3%) | 10/29 (34.5%) | 16/29 (55.2%) | |||
| Cardiac disorders | ||||||
| Palpitations | 0/26 (0%) | 0 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
| Eye disorders | ||||||
| Chalazion | 0/26 (0%) | 0 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
| Dry eye | 0/26 (0%) | 0 | 1/29 (3.4%) | 1 | 0/29 (0%) | 0 |
| Gastrointestinal disorders | ||||||
| Abdominal discomfort | 2/26 (7.7%) | 2 | 0/29 (0%) | 0 | 0/29 (0%) | 0 |
| Abdominal distension | 0/26 (0%) | 0 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
| Abdominal pain | 0/26 (0%) | 0 | 0/29 (0%) | 0 | 2/29 (6.9%) | 2 |
| Constipation | 1/26 (3.8%) | 1 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
| Diarrhoea | 1/26 (3.8%) | 1 | 0/29 (0%) | 0 | 2/29 (6.9%) | 2 |
| Dry mouth | 1/26 (3.8%) | 1 | 0/29 (0%) | 0 | 0/29 (0%) | 0 |
| Dyspepsia | 2/26 (7.7%) | 2 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
| Faeces hard | 0/26 (0%) | 0 | 1/29 (3.4%) | 1 | 0/29 (0%) | 0 |
| Flatulence | 1/26 (3.8%) | 1 | 1/29 (3.4%) | 1 | 0/29 (0%) | 0 |
| Gastrooesophageal reflux disease | 0/26 (0%) | 0 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
| Gingival pain | 1/26 (3.8%) | 1 | 0/29 (0%) | 0 | 0/29 (0%) | 0 |
| Haematochezia | 0/26 (0%) | 0 | 1/29 (3.4%) | 1 | 0/29 (0%) | 0 |
| Lip dry | 0/26 (0%) | 0 | 1/29 (3.4%) | 1 | 1/29 (3.4%) | 1 |
| Nausea | 1/26 (3.8%) | 2 | 0/29 (0%) | 0 | 4/29 (13.8%) | 6 |
| Toothache | 1/26 (3.8%) | 1 | 0/29 (0%) | 0 | 0/29 (0%) | 0 |
| Vomiting | 1/26 (3.8%) | 1 | 1/29 (3.4%) | 1 | 2/29 (6.9%) | 2 |
| General disorders | ||||||
| Fatigue | 3/26 (11.5%) | 3 | 1/29 (3.4%) | 1 | 2/29 (6.9%) | 2 |
| Feeling jittery | 0/26 (0%) | 0 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
| Injection site pain | 2/26 (7.7%) | 2 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
| Pyrexia | 0/26 (0%) | 0 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
| Swelling | 1/26 (3.8%) | 1 | 0/29 (0%) | 0 | 0/29 (0%) | 0 |
| Vessel puncture site haematoma | 0/26 (0%) | 0 | 1/29 (3.4%) | 1 | 1/29 (3.4%) | 1 |
| Immune system disorders | ||||||
| Seasonal allergy | 0/26 (0%) | 0 | 1/29 (3.4%) | 1 | 0/29 (0%) | 0 |
| Infections and infestations | ||||||
| Trichomoniasis | 0/26 (0%) | 0 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
| Injury, poisoning and procedural complications | ||||||
| Arthropod bite | 1/26 (3.8%) | 2 | 0/29 (0%) | 0 | 0/29 (0%) | 0 |
| Contusion | 1/26 (3.8%) | 1 | 0/29 (0%) | 0 | 0/29 (0%) | 0 |
| Metabolism and nutrition disorders | ||||||
| Decreased appetite | 1/26 (3.8%) | 1 | 0/29 (0%) | 0 | 4/29 (13.8%) | 5 |
| Dehydration | 0/26 (0%) | 0 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
| Hypoglycaemia | 1/26 (3.8%) | 2 | 1/29 (3.4%) | 1 | 4/29 (13.8%) | 12 |
| Musculoskeletal and connective tissue disorders | ||||||
| Back pain | 0/26 (0%) | 0 | 0/29 (0%) | 0 | 2/29 (6.9%) | 2 |
| Nervous system disorders | ||||||
| Dizziness | 0/26 (0%) | 0 | 1/29 (3.4%) | 4 | 1/29 (3.4%) | 1 |
| Dizziness postural | 0/26 (0%) | 0 | 1/29 (3.4%) | 1 | 0/29 (0%) | 0 |
| Headache | 4/26 (15.4%) | 4 | 1/29 (3.4%) | 1 | 5/29 (17.2%) | 5 |
| Paraesthesia | 0/26 (0%) | 0 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
| Sinus headache | 1/26 (3.8%) | 1 | 0/29 (0%) | 0 | 0/29 (0%) | 0 |
| Somnolence | 0/26 (0%) | 0 | 2/29 (6.9%) | 3 | 0/29 (0%) | 0 |
| Psychiatric disorders | ||||||
| Insomnia | 1/26 (3.8%) | 1 | 0/29 (0%) | 0 | 0/29 (0%) | 0 |
| Restlessness | 1/26 (3.8%) | 1 | 0/29 (0%) | 0 | 0/29 (0%) | 0 |
| Respiratory, thoracic and mediastinal disorders | ||||||
| Dyspnoea | 0/26 (0%) | 0 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
| Nasal congestion | 1/26 (3.8%) | 1 | 0/29 (0%) | 0 | 0/29 (0%) | 0 |
| Productive cough | 0/26 (0%) | 0 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
| Skin and subcutaneous tissue disorders | ||||||
| Hyperhidrosis | 0/26 (0%) | 0 | 0/29 (0%) | 0 | 1/29 (3.4%) | 1 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
Results Point of Contact
| Name/Title | Chief Medical Officer |
|---|---|
| Organization | Eli Lilly and Company |
| Phone | 800-545-5979 |
- 14361
- H9X-MC-GBDW